Abstract Exogenous melatonin (0.5-10 mg) has been shown to entrain the freerunning circadian rhythms of some blind subjects. The aim of this study was to assess further the entraining effects of a daily dose of 0.5 mg melatonin on the cortisol rhythm and its acute effects on subjective sleep in blind subjects with free-running 6-sulphatoxymelatonin (aMT6s) rhythms (circadian period [τ] 24.23-24.95 h). Ten subjects (9 males) were studied, aged 32 to 65 years, with no conscious light perception (NPL). In a placebo-controlled, single-blind design, subjects received 0.5 mg melatonin or placebo p.o. daily at 2100 h (treatment duration 26-81 days depending on individuals' circadian period). Subjective sleep was assessed from daily sleep and nap diaries. Urinary cortisol and aMT6s were assessed for 24 to 48 h weekly and measured by radioimmunoassay. Seven subjects exhibited an entrained or shortened cortisol period during melatonin treatment. Of these, 4 subjects entrained with a period indistinguishable from 24 h, 2 subjects continued to free run for up to 25 days during melatonin treatment before their cortisol rhythm became entrained, and 1 subject appeared to exhibit a shortened cortisol period throughout melatonin treatment. The subjects who entrained within 7 days did so when melatonin treatment commenced in the phase advance portion of the melatonin PRC (CT6-18). When melatonin treatment ceased, cortisol and aMT6s rhythms free ran at a similar period to before treatment. Three subjects failed to entrain with initial melatonin treatment commencing in the phase delay portion of the PRC. During melatonin treatment, there was a significant increase in nighttime sleep duration and a reduction in the number and duration of daytime naps. The positive effect of melatonin on sleep may be partly due to its acute soporific properties. The findings demonstrate that a daily dose of 0.5 mg melatonin is effective at entraining the free-running circadian systems in most of the blind subjects studied, and that circadian time (CT) of administration of melatonin may be important in determining whether a subject entrains to melatonin treatment. Optimal treatment with melatonin for this non-24-h sleep disorder should correct the underlying circadian disorder (to entrain the sleep-wake cycle) in addition to improving sleep acutely.
activity onset and the time of melatonin administration was achieved. The phase-advancing effects of melatonin were first documented in humans by Arendt et al. (1985) . Near-symmetrical phase response curves (PRC) describing both advances and delays have since been established for melatonin administration (Lewy et al., 1992; Zaidan et al., 1994; Middleton et al., 1997; Lewy et al., 1998) , although there is some debate as to whether it can consistently induce phase delays (Wirz-Justice et al., 2002) .
The results of previous investigations of the ability of melatonin to entrain a desynchronized circadian system in sighted humans remain ambiguous. Exogenous melatonin (5 mg) appeared to stabilize (but not necessarily entrain) sleep-wake cycles but failed to entrain core body temperature rhythms consistently in sighted humans when administered daily for 16 days . The 24-h period of the sleep-wake cycle in the presence of a nonentrained circadian system suggests that melatonin's soporific properties may account for the apparent stabilization of sleep. A similar observation was made in a free-running totally blind man, who demonstrated stabilization of the sleep-wake cycle during melatonin treatment, whereas the underlying circadian rhythms of cortisol and temperature continued to free run with an unchanged period Folkard et al., 1990) . Later attempts to correct sleep disorders in freerunning blind subjects resulted in an apparent improvement in sleep with either no entrainment or a shortening of the period of endogenous circadian rhythms (Sack et al., 1991; Lapierre and Dumont, 1995; Jan and O'Donnell, 1996; Arendt et al., 1997; Palm et al., 1997; . In contrast, several recent studies have reexamined the ability of melatonin to entrain free-running rhythms in totally blind people and found that entrainment could be achieved following daily oral melatonin treatment with 5-mg (Lockley et al., 2000) , 10-mg (Sack et al., 2000) , or 0.5-mg doses (Lewy et al., 2001a ). An individual with a period as long as 24.9 h (Lewy et al., 2002) has been shown to entrain using such a regime. This lack of concordance between the magnitude of phase shifting reported in the melatonin PRC data (up tõ 1.5 h advance and delay) and the daily advance required to entrain most free-running blind people (< 1 h/day) remains unresolved. Possible explanations include dose and/or duration of melatonin treatment, individual PRC characteristics, individual differences in melatonin pharmacokinetics, or melatonin receptor number or sensitivity, although these have yet to be investigated systematically.
Previous studies have shown that chronic usage of melatonin is necessary for free-running blind people to remain entrained to the 24-h day (Lockley et al., 2000; Sack et al., 2000; Lewy et al., 2001a) . Therefore, a lower dose would always be preferable to a higher dose for long-term treatment in order to reduce possible side effects. The aims of this study were to assess further the ability of 0.5 mg melatonin to entrain the endogenous free-running circadian system of totally blind subjects, as well as investigate its acute effects on sleep and the relationship between entrainment, circadian period, and phase of melatonin treatment.
MATERIALS AND METHOD

Subjects
Ten totally blind subjects (9 males, 1 female) were studied. Subject details are shown in Table 1 . The University of Surrey Advisory Committee on Ethics approved the study, and all subjects gave informed consent. Throughout the study, subjects were instructed not to take any medication that could affect melatonin or cortisol production or sleep (e.g., β-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, and benzodiazepines). All subjects were confirmed as having free-running 6-sulphatoxymelatonin (aMT6s) rhythms prior to commencing melatonin treatment (τ range: 24.30-24.96 h) (Table 1) . Briefly, this consisted of a 4-week field study in which subjects collected sequential 4-hourly (8 hourly overnight) urines for 48 h at weekly intervals for the assessment of aMT6s rhythmicity (for details, see Lockley et al., 1997a) .
Study Design
Subjects were assessed for 15 to 36 weeks depending on their endogenous circadian period. They kept daily sleep and nap diaries and collected sequential 4-hourly (8-hourly overnight) urines for 24 or 48 h at weekly intervals for the assessment of aMT6s and cortisol by radioimmunoassay (RIA).
In a placebo-controlled, single-blind design, subjects received 0.5 mg melatonin p.o. (Penn Pharmaceuticals, Tredegar, Gwent, UK) or placebo (identical lactose-filled capsule) daily at 2100 h for at least one full circadian beat cycle according to their baseline aMT6s period (range of treatment: 26-81 days) (i.e., the number of days to complete one full cycle, 360 degrees). All subjects received both treatments. Table 1 shows the duration of treatment for each subject.
Sleep Analysis
The following sleep and nap parameters were derived from the sleep diaries: sleep latency (time to fall asleep), sleep onset, number and duration of night awakenings, sleep offset, total night sleep duration, sleep quality (rated on a 1 to 9 scale, with 1 = best and 9 = worst), and number and duration of naps. For each subject, the daily nap parameters during placebo and melatonin treatments were compared using unpaired Student's t tests. Each subject's sleep parameters were averaged and compared for each treatment condition using paired Student's t tests. Data obtained when neither placebo nor melatonin was taken were excluded from any sleep analysis.
Assays
Urinary aMT6s levels were measured by RIA with reagents donated by Stockgrand Ltd., University of Surrey, United Kingdom. The limit of sensitivity for the assay was 1.9 ng/ mL. The interassay coefficients of variation (CV) were 17% at 3 ng/mL (low batch 1, n = 23), 20% at 4 ng/mL (low batch 2, n = 32), 12% at 24 ng/mL (n = 57), and 8% at 44 ng/mL (n = 51).
Urinary cortisol was extracted using dichloromethane and measured by RIA (Riad-Fahmy et al., 1979) using an antiserum raised in sheep (Scottish Antiserum Production Unit, UK) and an iodinated radiolabel (Amersham International, UK). The limit of sensitivity for the assay was 14.5 nmol/L. The interassay CVs were 14% at 51 nmol/L (n = 53), 20% at 162 nmol/L (medium batch 1, n = 20), 15% at 93 nmol/L (medium batch 2, n = 3), 20% at 144 nmol/L (medium batch 3, n = 23), and 15% at 763 nmol/L (n = 55).
Rhythm Analysis
The methods used to determine the characteristics of urinary aMT6s and cortisol rhythms have been detailed elsewhere (Lockley et al., 1997a; Skene et al., 1999; Lockley et al., 2000) . Briefly, acrophase times for aMT6s (ng/h) and cortisol (nmol/h) were determined by cosinor analysis (Nelson et al., 1979 ) using a program written by Dr. D. S. Minors, University of Manchester, United Kingdom. Cosinor-derived acrophase times were used for further analysis if the probability of fit (p) was < 0.05 for aMT6s and < 0.20 for cortisol (Lockley et al., 2000) . Midrange crossing analysis (the midpoint of the upward and downward mean crossing times) (Lockley et al., 2000) was used to validate phase and period estimates from cosinor analysis. One subject (S44) had insufficient aMT6s acrophases derived from cosinor analysis to perform regression analysis, so the period was determined by midrange crossing analysis. The slope of the best-fit line fitted through statistically significant acrophase times was used to calculate the period of the rhythm (±95% confidence limits) (Lockley et al., 1997a) . The period was considered to be a free-running rhythm (i.e., not entrained to 24 h) if the 95% confidence limits of the regression analysis did not cross 0 and entrained if the 95% limits crossed 0. In three cases in which there were large 95% confidence limits, however, the rhythm was considered free running when the period > 24.3 h. Pla- cebo and no-treatment data prior to melatonin treatment were combined for period determination. In subjects who did not appear to entrain within 7 days upon visual inspection of the data, the point at which they entrained was established by determining the first acrophase that was not within the 95% confidence limits extrapolated from the premelatonin treatment cortisol regression analysis. The preceding acrophase was taken as the 1st day of entrainment. This analysis was not possible for 1 subject (S78) who appeared to have exhibited a phase shift within the first few days of melatonin. In this subject, day 25 was therefore taken as the 1st day of entrainment as regression analysis of the acrophases after this point gave a period close to 24 h. The average cortisol phase was calculated in entrained subjects and considered normal when it fell within the range previously determined in stably entrained blind subjects (mean ± SD = 9.9 ± 1.8 h) . The circadian time (CT) at which the 1st melatonin capsule was taken was calculated by extrapolation of the aMT6s period prior to melatonin treatment, with aMT6s acrophase designated as CT21 (Lockley et al., 2000) . For subjects who did not entrain within 7 days, the CT for the 1st day that they were entrained was calculated using the 1st cortisol acrophase that was considered to be entrained and expressed relative to aMT6s phase using the individual's average phase angle between cortisol and aMT6s acrophases from premelatonin data. The cortisol and aMT6s periods before and after melatonin treatment were also compared (paired Student's t tests) to examine any persistent effect of melatonin treatment on period.
RESULTS aMT6s and Cortisol Production
The subjects' endogenous production of urinary aMT6s and cortisol (mean ± SD) ranged from 5.8 ± 2.7 to 36.9 ± 8.6 µg/24 h and 43.3 ± 12.5 to 164.0 ± 50.6 nmol/24 h during placebo treatment, respectively, both within the normal ranges for blind subjects (mean ± 2SD; aMT6s: 11.0 ± 14.0 µg/24 h, n = 50; cortisol: 89.2 ± 82.7 nmol/24 h, n = 51) (Lockley et al., unpublished data) . There was no significant difference in daily aMT6s and cortisol production between subjects who did and did not entrain. For analysis of subjects who entrained after a lag period, the free-running data at the beginning of the melatonin treatment were grouped with the placebo data. There was no significant difference in 24-h cortisol output between melatonin and placebo treatments.
During melatonin treatment, endogenous aMT6s levels increased on average 23-fold (range: 8-to 42-fold), confirming subject compliance with the order of treatment.
There was a good correlation between cortisol and aMT6s periods (assessed by cosinor analysis) prior to melatonin treatment (r = 0.85). There was also a good correlation between acrophases and periods derived by cosinor analysis and midpoint crossing analysis for both aMT6s (acrophase r = 0.86; period r = 0.88) and cortisol (acrophase r = 0.76; period r = 0.97) rhythms. There was a differential effect of melatonin treatment on entrainment of the cortisol rhythm. Six of the 10 subjects had an entrained cortisol period during melatonin treatment, with 4 of the subjects having a period that was indistinguishable from 24 h (τ range: 23.99-24.01 h) (Table 2a ; Fig. 1a) . The CT at which melatonin commenced in these 4 subjects ranged from CT10 to CT16 (Table 2a ). The other 2 subjects (S51, S78) continued to free run during the initial part of the melatonin treatment (CT of first melatonin dose was CT22 and CT3, respectively). In the case of 1 of these subjects (S78), a phase shift appears to have occurred within the first few days of melatonin treatment, but with an unchanged period for 25 days (24.32 ± 0.79 h). The cortisol rhythm became entrained with a period indistinguishable from 24 h in S51 (24.02 h) (Fig. 1b) and S78 (23.99 h) after 18 and 25 days, respectively. The calculated CT of melatonin administration on these days was CT10 and CT11, respectively (Table  2b) .
Effects of Melatonin Treatment on Entrainment
One subject (S45) appeared to exhibit a shortened cortisol period (24.45 ± 2.48 h) during melatonin treatment (Table 2c , Fig. 1c ). This subject had a small number of data points because of the subject's long τ and consequent short duration of melatonin treatment (i.e., when τ = 24.95 h, it takes only 26 days to complete one full cycle of τ and T = 24.00 h). Analysis by midrange crossing points confirmed a shortened period of 24.46 h. In addition, the timing of naps also suggests a shortened period, in that the number of days between episodes of daytime napping associated with circadian desynchrony (Lockley et al., 1997b ) is increased during the melatonin treatment in this subject, suggesting a longer beat cycle consistent with a shorter period (Fig. 1c, right panel) .
The 6 subjects who entrained to melatonin had a mean cortisol acrophase (± SD) of 11.3 ± 1.1 h within the range for normally entrained blind subjects (mean ± 2SD = 9.9 ± 3.6 h , indicating that they were all entrained to a normal circadian phase. The mean (± SD) acrophase (decimal time) for each entrained subject was 10.3 ± 1.4 h (S44), 10.5 ± 1.0 h (S51), 10.6 ± 0.1 h (S70), 11.2 ± 0.6 h (S78), 12.3 ± 0.2 h (S79), and 13.1 ± 1.9 h (S77).
Three subjects failed to entrain to melatonin treatment. In these subjects, treatment commenced at CT3, CT18, and CT22 (Table 2d ). Their cortisol period did not differ during melatonin treatment compared to placebo (Table 2d ; Fig. 1d) .
In those subjects from whom both pre-and posttreatment periods were available for analysis (n = 6), there was no significant difference in the cortisol periods before and after melatonin treatment.
Effects of Melatonin on Sleep
Melatonin significantly improved at least one measure of subjective sleep in 9 of 10 subjects. Compared to placebo, melatonin significantly affected a number of sleep parameters (Table 3) . Melatonin had a marked effect on napping, significantly reducing the number (t = 4.341, df = 9, p = 0.002) and duration (t = 3.295, df = 9, p = 0.009) of naps compared to placebo (paired Student's t test) (Table 3) . Melatonin treatment also significantly delayed sleep offset (t = 2.704, df = 9, p = 0.02), decreased the duration of night awakenings (t = 2.504, df = 9, p = 0.03) and increased total night sleep duration (t = 3.470, df = 9, p = 0.007) (paired Student's t test). Figure 2 shows the average number and duration of naps in each subject during placebo and melatonin treatment. Significant differences (shown as solid lines in Fig. 2 ) between treatments were observed in 6 of 10 subjects (number of naps) and 7 of 10 subjects (duration of naps).
DISCUSSION
The present results show that appropriately timed, low-dose melatonin (0.5 mg) can entrain free-running circadian rhythms in most blind people. This finding confirms and extends a previous report of entrainment of 3 free-running blind people with 0.5 mg melatonin (Lewy et al., 2001a) . In agreement with our previous study with 5 mg melatonin (Lockley et al., 2000) , entrainment was more likely when melatonin treatment was started in the phase advance portion of the melatonin PRC (CT6-18). When 0.5 mg melatonin 424 JOURNAL OF BIOLOGICAL RHYTHMS / October 2003 was started in the phase delay region of the PRC, some individuals did not exhibit changes in phase or period during melatonin administration and continued to free run, again in agreement with the 5-mg studies (Lockley et al., 2000) . In contrast to our previous findings, however, we have shown here that when 0.5 mg melatonin is initially administered in the phase delay portion of the PRC, free-running rhythms can eventually become entrained in some individuals when an appropriate circadian time for melatonin administration is reached, analogous to the first study in mammals (Redman et al., 1983) . The current study confirms and extends our finding that the CT of administration of melatonin is an important factor in determining whether entrainment occurs (Lockley et al., 2000) . All subjects in the current study had an endogenous period > 24 h and therefore required a net advance in phase to become entrained to 24 h. The published PRCs for melatonin predict that 5.99 ± 0.88 6.64 ± 1.11** Sleep quality (1-9 scale, with 1 = best and 9 = worst) 4.85 ± 0.80 4.70 ± 0.95 Number of naps/day 1.09 ± 1.45 0.76 ± 1.27** Duration of naps/day (h) 0.45 ± 0.35 0.14 ± 0.12** *p < 0.05. **p < 0.01 compared with placebo (paired Student's t test).
phase advances will occur when melatonin is administered between~CT6 and CT18 (if CT14 represents plasma melatonin onset and CT21 represents urinary aMT6s peak). The subjects who entrained within 7 days did so when melatonin treatment commenced in this region of the PRC. Subjects who entrained part way through treatment also became entrained once the timing of melatonin treatment was within the phase advance region (CT10, CT11). Subjects who did not entrain at all (n = 3) started melatonin treatment in the delay region or close to the "crossover" portion of the PRC. It is not clear why these few subjects did not become entrained later when melatonin treatment coincided with the phase advance portion of the PRC. While it would have been desirable to start and treat all subjects at the same circadian time in the advance portion of the melatonin PRC, this is presently exceedingly difficult to do in field studies such as this. Ideally, the subjects who did not entrain should be restudied with melatonin treatment starting in the phase advance portion of the melatonin PRC. This would clarify the role of the circadian phase of treatment in the ability of melatonin to entrain the circadian system. One reason for the apparent lack of entrainment may be the shortened duration of melatonin treatment the subjects received. If these subjects were treated with melatonin for longer, then entrainment may have occurred.
Determining why interindividual differences exist with respect to the efficacy of entrainment by melatonin is vital to the development of melatonin administration regimes applicable to a general population in the treatment of free-running circadian rhythms and non-24-hr sleep-wake disorder (Lockley et al., 1997b . The present finding that melatonin administration can entrain some, but not all, subjects when their endogenous circadian phase "drifts" into an appropriate phase relationship with the treatment time, rather than having to initiate treatment at an appropriate phase, has the potential to make treatment regimes easier to develop. Within an individual, both dose and circadian time may play a role. For example, one of the individuals (S51) who entrained after a lag with 0.5 mg melatonin failed to entrain when 5 mg melatonin was started at CT3 (Lockley et al., 2000) but entrained when 5 mg was started at CT7 (Lockley et al., unpublished results) .
Overall, there does not appear to be a dose-dependent difference in the efficacy of melatonin to entrain free-running circadian rhythms in the blind. In the current study, 6 of 10 (60%) subjects became entrained, and 1 of 10 (10%) appeared to have a shortened period. In our previous study using a 10-fold higher dose (Lockley et al., 2000) , 3 of 7 (43%) entrained and 1 of 7 (14%) had a shortened period. The limits of entrainment (based on the subjects' period) also do not appear to differ between the two doses (see below). One explanation for the lack of a clear dose-dependent effect is that both doses produce supraphysiological levels of circulating plasma melatonin shortly after ingestion that may be indistinguishable at a receptor level. Melatonin pharmacokinetics are known to vary greatly between individuals (Aldhous et al., 1985) , and there may be individual differences in feedback of high circulating melatonin levels on the number and sensitivity of melatonin receptors (Gauer et al., 1993) . Another question is whether the differences in period between individuals, and therefore the relative zeitgeber strength of melatonin required to entrain, determined whether entrainment occurred. A clear relationship is not apparent from the relatively small group of subjects presented here, as the range in aMT6s period overlaps between those who entrained (24.23-24.39 h), those who entrained after a lag (24.27-24.73 h), or those who failed to entrain (24.28-24.61 h). Thus, it is difficult to draw any conclusions about the relationship between individual period and entrainment by 0.5 mg melatonin from this study. In a previous case study of 0.5 mg melatonin administration given in the phase advance region of the PRC to freerunning blind individuals, those who became entrained had periods of 24.3, 24.4, and 24.5 h (Lewy et al., 2001a) . Entrainment using higher doses of melatonin and other treatment regimes suggest similar limits of entrainment; up to 24.57 h (Lockley et al., 2000) and 24.62 h (Lockley et al., unpublished results) using a daily 5-mg dose, up to 24.6 h using a daily 10-mg dose, and up to 24.4 h when a 10-mg dose was gradually stepped down to 0.5 mg over 12 weeks (Sack et al., 2000) , although to date no systematic study of the limits of entrainment for melatonin administration has been conducted. Lewy and colleagues predicted that periods τ ≥ 24.75 h cannot be entrained by melatonin when their published PRC (Lewy et al., 1998 ) is used to predict the phase angle of entrainment between melatonin administration time and the endogenous melatonin onset (Lewy et al., 2001b) . These findings are inconsistent with the claim that entrainment was observed in a subject with a period of 24.9 h using 7.5 mg melatonin daily (Sack et al., 1991) and after 47 days of the 0.5-mg treatment (Lewy et al., 2002) . Further work is required to establish the range of entrainment to different doses of melatonin and how applicable such ranges are to a wider population in designing clinical treatments.
The subject (S45) with the longest period (24.96 h) appeared to show a shortening of period with 0.5 mg melatonin. As period shortened during the treatment, melatonin was not administered for a full beat cycle. It is not known, and as yet untested, whether entrainment would have occurred if the treatment were extended. A 5-mg dose of melatonin was also previously unsuccessful in entraining this individual when administered either at a phase advance (Lockley et al., 2000) or phase delay (Lockley et al., unpublished results) portion of the PRC, suggesting that insufficient dose or circadian phase is an unlikely explanation for the lack of entrainment. The shortening of the > 24.9 h period by a lower dose of melatonin suggests that 0.5 mg melatonin can produce phase advances of 0.4 h but not the~1 h advance required to entrain. Recently, Lewy and colleagues (2002) have reported a similar finding in an individual with a similarly long period (24.9 h) who also did not entrain to 10 mg or 20 mg but did entrain after a period of 47 days when administered 0.5 mg daily melatonin. The long endogenous period of both individuals and the apparently counterintuitive response to dose suggest that there are complex interactions between dose and an individual's period, PRC, and limits of entrainment to melatonin. Caution is required, however, if melatonin treatment results in a shortening of period rather than entrainment, as this would result in longer episodes of poorer sleep by lengthening the duration of circadian misalignment. Although the episodes of good sleep would also be equally extended, the longer duration of poor sleep may have a greater impact due to cumulative chronic sleep loss.
The aim of developing melatonin treatment regimes to entrain the underlying circadian oscillator is to optimally treat the clinical "non-24-h sleep-wake disorder" condition that develops as a result of misalignment of the circadian system with the social 24-h day. It is characterized by cyclic episodes of poor sleep and increased daytime napping when the circadian system is out of phase with the 24-h day (identified by aMT6s acrophase at an abnormal phase, 0600-2400 h), followed by episodes of better sleep and improved daytime alertness when the aMT6s rhythm is at a relatively normal circadian phase (2400-0600 h) (Lockley et al., 1997b . Free-running rhythms in sleep, without other endogenous circadian rhythm markers, are not always readily observed in field studies due to social factors such as the necessity to keep standard working hours.
Despite a differential effect on entrainment, melatonin improved at least one aspect of subjective sleep in virtually all subjects. In the nonentrained individuals, these effects may be solely due to the soporific effects of exogenous melatonin. The direct soporific effects of melatonin on nighttime sleep in normal subjects have been described as modest (e.g., . The advantage of using the phase-shifting properties of melatonin to treat non-24-h sleep-wake disorder is based on the fact that sleep quality and quantity are maximal if sleep occurs at the optimal circadian phase (Czeisler et al., 1980; Dijk and Czeisler, 1994) , and it appears that even a small degree of desynchrony may result in insomnia symptoms (Morris et al., 1990) . Recent evidence in the blind suggests that if the circadian system continues to free run during melatonin treatment, the sleep-wake cycle also continues to free run, despite the acute sleep-improving effects of melatonin (Lockley et al., unpublished results) , and thus the underlying cause of the sleep disorder remains untreated. Our findings indicate that optimal treatment for non-24-h sleep disorder should use both the soporific and chronobiotic properties of melatonin by giving melatonin close to the desired bedtime and at the correct circadian phasenamely, the phase advance portion of the melatonin PRC. An acute improvement of sleep alone without reentrainment will fail to treat the underlying circadian disorder and only mask the influence of circadian phase on sleep , although the quality and composition of such sleep remain to be investigated.
In conclusion, the current study confirms in a larger population than previously assessed that 0.5 mg can entrain the free-running circadian system of blind subjects. The findings also show that entrainment depends on the circadian phase of melatonin administration. Melatonin administered initially in the phase advance portion of the PRC will entrain most free-running subjects, whereas melatonin initially given in the phase delay portion will not entrain the majority of these subjects. Furthermore, we have demonstrated that some individuals will free run until the appropriate phase is reached before becoming entrained, in agreement with the first demonstration of entrainment by melatonin in mammals (Redman et al., 1983) .
